Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O75911
UPID:
DHRS3_HUMAN
Alternative names:
DD83.1; Retinal short-chain dehydrogenase/reductase 1; Retinol dehydrogenase 17; Short chain dehydrogenase/reductase family 16C member 1
Alternative UPACC:
O75911; B2R7F3; Q5VUY3; Q6UY38; Q9BUC8
Background:
Short-chain dehydrogenase/reductase 3, known by alternative names such as DD83.1, Retinal short-chain dehydrogenase/reductase 1, Retinol dehydrogenase 17, and Short chain dehydrogenase/reductase family 16C member 1, plays a crucial role in the visual cycle. It catalyzes the reduction of all-trans-retinal to all-trans-retinol in the presence of NADPH, a key step in the regeneration of the visual pigment rhodopsin.
Therapeutic significance:
Understanding the role of Short-chain dehydrogenase/reductase 3 could open doors to potential therapeutic strategies.